An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Abroad (travel likely)RecruitingPHASE2

Conditions

Progressive Pulmonary Fibrosis · Idiopathic Pulmonary Fibrosis (IPF)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • University of Alabama at Birmingham, Birmingham, Alabama, United States

    Contact: Principal Investigator (Tejaswini Kulkarni)
  • University of Southern California, Los Angeles, California, United States

    Contact: Principal Investigator (Toby Maher)
  • University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States

    Contact: Study coordinator (Joyce Lee)
    Contact: Principal Investigator (Joyce Lee, MD)
  • Renstar Medical Research, Ocala, Florida, United States

    Contact: Study coordinator (Raj Karunakara)
    Contact: Principal Investigator (Raj Karunakara, MD)
  • Piedmont Healthcare, Inc., Atlanta, Georgia, United States

    Contact: Study coordinator (Amy Case)
    Contact: Principal Investigator (Amy Case, MD)
  • The University of Kansas Medical Center, Kansas City, Kansas, United States

    Contact: Study coordinator (Mark Hamblin, MD)
    Contact: Principal Investigator (Mark Hamblin, MD)
  • University of Maryland, Baltimore, Maryland, United States

    Contact: Principal Investigator (Edward Britt)
  • Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, United States

    Contact: Principal Investigator (Matthew Lammi, MD)
  • Mayo Clinic Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Andrew Limper)
    Contact: Study coordinator (Sam Nascak)
    Contact: Principal Investigator (Andrew Limper, MD)
  • Hannibal Regional Healthcare System, Inc., Hannibal, Missouri, United States

    Contact: Study coordinator (Humam Farah, MD)
    Contact: Principal Investigator (Humam Farah, MD)
  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

    Contact: Study coordinator (Maria Padilla)
    Contact: Principal Investigator (Maria Padilla, MD)
  • Columbia University, New York, New York, United States

    Contact: Study coordinator (Claire McGroder)
    Contact: Principal Investigator (Claire McGroder, MD)
  • Piedmont HealthCare, PA, Statesville, North Carolina, United States

    Contact: Study coordinator (Jose Perez)
    Contact: Principal Investigator (Jose Perez, MD)
  • Southeastern Research Center, Winston-Salem, North Carolina, United States

    Contact: Study coordinator (Jason Thomason) · 336-765-0383
    Contact: Principal Investigator (Jason Thomason, MD)
  • University of Cincinnati, Cincinnati, Ohio, United States

    Contact: Study coordinator (Nishant Gupta)
    Contact: Principal Investigator (Nishant Gupta, MD)
  • Summit Health, Bend, Oregon, United States

    Contact: Study coordinator (Jeremy Feldman, MD)
    Contact: Principal Investigator (Jeremy Feldman, MD)
  • Thomas Jefferson University, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Ross Summer)
    Contact: Principal Investigator (Ross Summer, MD)
  • Temple University Hospital, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Gerard Criner, MD)
    Contact: Principal Investigator (Gerard Criner, MD)
  • Lowcountry Lung and Critical Care, PA, Charleston, South Carolina, United States

    Contact: Study coordinator (Thomas Kaelin, Jr, DO)
    Contact: Principal Investigator (Thomas Kaelin, Jr., DO)
  • Medical University of South Carolina, Charleston, South Carolina, United States

    Contact: Study coordinator (Timothy Whelan)
    Contact: Principal Investigator (Timothy Whelan, MD)
  • Vanderbilt University Medical Center, Nashville, Tennessee, United States

    Contact: Study coordinator (Justin Hewlett, MD)
    Contact: Principal Investigator (Justin Hewlett, MD)
  • El Paso Pulmonary Association, P.A., El Paso, Texas, United States

    Contact: Study coordinator (Carlo Hatem, MD)
    Contact: Principal Investigator (Carlo Hatem, MD)
  • Intermountain Medical Center, Murray, Utah, United States

    Contact: Study coordinator (Peter Crossno, MD)
    Contact: Principal Investigator (Peter Crossno, MD)
  • University of Utah, Salt Lake City, Utah, United States

    Contact: Principal Investigator (Mary Beth Scholand, MD)
  • Inova Healthcare, Falls Church, Virginia, United States

    Contact: Principal Investigator (Vikramjit Khangoora)
  • Westmead Hospital, Westmead, New South Wales, Australia

    Contact: Study coordinator (John Wheatley) · john.wheatley@sydney.edu.au · 000-000-000
    Contact: Principal Investigator (John Wheatley)
  • The Queen Elizabeth Hospital, Woodville South, South Australia, Australia

  • Royal Prince Alfred Hospital, Camperdown, Australia

    Contact: Study coordinator (Tamera Corte) · tamera.corte@health.nsw.gov.au · (02) 95156120
    Contact: Principal Investigator (Tamera Corte)
  • The Prince Charles Hospital (TPCH), Chermside, Australia

    Contact: Study coordinator (Peter Hopkins) · peter_hopkins@health.qld.gov.au · 000-000-000
    Contact: Principal Investigator (Peter Hopkins)
  • Lung & Sleep Victoria, Footscray, Australia

    Contact: Study coordinator (Ian Glaspole)
    Contact: Principal Investigator (Ian Glaspole)
  • Respiratory Clinical Trials PTY Ltd, Kent Town, Australia

    Contact: Study coordinator (Michael Chia) · mmchia@hotmail.com · 000-000-000
    Contact: Principal Investigator (Michael Chia)
  • Nepean Lung & Sleep, Kingston, Australia

    Contact: Study coordinator (Donald Lee)
    Contact: Principal Investigator (Donald Lee)
  • Univ of Western Australia / Institute for Respiratory Health, Nedlands, Australia

    Contact: Study coordinator (Vidya Navaratnam) · Vidya.Navaratnam@health.wa.gov.au · 000-000-000
    Contact: Principal Investigator (Vidya Navaratnam)
  • John Hunter Hospital, New Lambton Heights, Australia

    Contact: Study coordinator (Christopher Grainge) · christopher.grainge@health.nsw.gov.au · 000-000-000
    Contact: Principal Investigator (Christopher Grainge)
  • Dynamic Drug Advancement, Ajax, Ontario, Canada

    Contact: Study coordinator (George Philteos) · 000-000-000
    Contact: Principal Investigator (George Philteos)
  • Research Institute McGill University Health Center, Montreal, Quebec, Canada

    Contact: Principal Investigator (Deborah Assayag)
  • CIC Mauricie, Trois-Rivières, Quebec, Canada

    Contact: Study coordinator (Emilie Millaire) · 000-000-000
    Contact: Principal Investigator (Emilie Millaire)
  • Centre for Lung Health, Vancouver, Vancouver, Canada

    Contact: Study coordinator (Daniel Marinescu) · 000-000-000
    Contact: Principal Investigator (Daniel Marinescu)
  • Fakultni Thomayerove nemocnice, Praha Klanovice, Czechia

    Contact: Study coordinator (Martina Sterclova) · martina.sterclova@ftn.cz · 000-000-000
    Contact: Principal Investigator (Martina Sterclova)
  • University of Montpellier, Montrevel-en-Bresse, Montpellier, France

    Contact: Study coordinator (Arnaud Bourdin) · 000-000-000
    Contact: Study coordinator (Arnaud Bourdin)
    Contact: Principal Investigator (Arnaud Bourdin)
  • Centre Hospitalier Universitaire d'Angers, Angers, France

    Contact: Study coordinator (Frederic Gagnadoux, MD)
  • Medizinische Hochschule Hannover, Hanover, Lower Saxony, Germany

    Contact: Principal Investigator (Jonas Schupp)
  • Fondazione IRCCS Policlinico San Matteo - UOC Pneumologia, Pavia, Lombardy, Italy

    Contact: Study coordinator (Angelo Guido Corsico, MD)
  • St Antonius Hospital, Nieuwegein, Netherlands

    Contact: Study coordinator (Marcel Veltkamp) · m.veltkamp@antoniusziekenhuis.nl · 0031 88 320 14 25
    Contact: Principal Investigator (Marcel Veltkamp)
  • Greenlane Clinical Centre, Auckland, Auckland, New Zealand

    Contact: Study coordinator (Margaret Wilsher) · mwilsher@adhb.govt.nz · 000-000-000
    Contact: Principal Investigator (Margaret Wilsher)
  • Bay of Plenty Clinical Trials Unit, Tauranga, Tauranga, New Zealand

    Contact: Principal Investigator (Suzanne Poole)
  • Dunedin Hospital, Dunedin, New Zealand

  • Waikato Hospital, Hamilton, New Zealand

    Contact: Study coordinator (Catherina Chang) · cat.chang@waikatodhb.health.nz · 000-000-000
    Contact: Principal Investigator (Catherina Chang)
  • Uniwersyteckie Centrum Kliniczne, Gdansk, Poland

    Contact: Study coordinator (Amelia Szymanowska-Narloch, MD)
  • Department of Pneumology of the University Hospital No 1, Lodz, Poland

    Contact: Study coordinator (Wojciech Piotrowski, MD, PhD)
  • Hospital Gregorio Marañon, Madrid, Madrid, Spain

    Contact: Study coordinator (Luis Puente Maestu) · 000-000-000
    Contact: Principal Investigator (Luis Puente Maestu)
  • Hull University Teaching Hospital, Cottingham, East Yorkshire, United Kingdom

    Contact: Principal Investigator (Simon Hart)
  • Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom

    Contact: Study coordinator (Helen Parfrey, MD)
  • Leicester Biomedical Research Centre, Leicester, United Kingdom

    Contact: Study coordinator (Charlotte Swales) · Charlotte.Swales@uhl-tr.nhs.uk · 0044116 2583825
    Contact: Principal Investigator (Charlotte Swales)
Study leads
  • Avalyn Pharma, Inc.

    Study Director

    Avalyn Pharma Inc.